CYP 5.26% 20.0¢ cynata therapeutics limited

Ann: Cynata Expands trial in COVID-19 & Respiratory Failure, page-166

  1. 1,192 Posts.
    lightbulb Created with Sketch. 3882

    The MEseNchymal coviD-19 Trial: MSCs in Adults With Respiratory Failure Due to COVID-19 or Another Underlying Cause (MEND)

    Now (yesterday) officially updated with VIC based hospitals also recruiting:

    https://hotcopper.com.au/data/attachments/3199/3199063-4c1553f66ff14ed73bad97c2c7e347dd.jpg

    https://clinicaltrials.gov/ct2/show/NCT04537351
 
watchlist Created with Sketch. Add CYP (ASX) to my watchlist
(20min delay)
Last
20.0¢
Change
0.010(5.26%)
Mkt cap ! $36.13M
Open High Low Value Volume
20.5¢ 20.5¢ 20.0¢ $8.749K 42.75K

Buyers (Bids)

No. Vol. Price($)
2 19130 19.0¢
 

Sellers (Offers)

Price($) Vol. No.
20.0¢ 20000 1
View Market Depth
Last trade - 13.09pm 06/09/2024 (20 minute delay) ?
CYP (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.